These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11562517)

  • 1. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme.
    Griffiths TL; Phillips CJ; Davies S; Burr ML; Campbell IA
    Thorax; 2001 Oct; 56(10):779-84. PubMed ID: 11562517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
    Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home-based pulmonary rehabilitation for COPD using minimal resources: An economic analysis.
    Burge AT; Holland AE; McDonald CF; Abramson MJ; Hill CJ; Lee AL; Cox NS; Moore R; Nicolson C; O'Halloran P; Lahham A; Gillies R; Mahal A
    Respirology; 2020 Feb; 25(2):183-190. PubMed ID: 31418515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of comprehensive cardiac telerehabilitation on one-year cardiovascular rehospitalization rate, medical costs and quality of life: A cost-effectiveness analysis.
    Frederix I; Hansen D; Coninx K; Vandervoort P; Vandijck D; Hens N; Van Craenenbroeck E; Van Driessche N; Dendale P
    Eur J Prev Cardiol; 2016 May; 23(7):674-82. PubMed ID: 26289723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical stabilisation of the spine compared with a programme of intensive rehabilitation for the management of patients with chronic low back pain: cost utility analysis based on a randomised controlled trial.
    Rivero-Arias O; Campbell H; Gray A; Fairbank J; Frost H; Wilson-MacDonald J
    BMJ; 2005 May; 330(7502):1239. PubMed ID: 15911536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of a three-month exercise programme vs usual care following multidisciplinary rehabilitation for chronic low back pain.
    Henchoz Y; Pinget C; Wasserfallen JB; Paillex R; de Goumoëns P; Norberg M; Kai-Lik So A
    J Rehabil Med; 2010 Oct; 42(9):846-52. PubMed ID: 20878045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.
    Stawowczyk E; Kawalec P; Pilc A
    Pharmacotherapy; 2016 May; 36(5):472-81. PubMed ID: 27007213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
    Manning VL; Kaambwa B; Ratcliffe J; Scott DL; Choy E; Hurley MV; Bearne LM
    Rheumatology (Oxford); 2015 Feb; 54(2):302-9. PubMed ID: 25173349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of telerehabilitation versus traditional care after total hip replacement: A trial-based economic evaluation.
    Nelson M; Russell T; Crossley K; Bourke M; McPhail S
    J Telemed Telecare; 2021 Jul; 27(6):359-366. PubMed ID: 31530065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of learning and coping versus standard education in cardiac rehabilitation: a randomised controlled trial with 3 years of follow-up.
    Tayyari Dehbarez N; Palmhøj Nielsen C; Risør BW; Vinther Nielsen C; Lynggaard V
    Open Heart; 2020; 7(1):e001184. PubMed ID: 32076564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.